Association between histone deacetylases and the loss of cochlear hair cells: Role of the former in noise-induced hearing loss

Wen,Li-Ting; Wang,Jie; Wang,Ye; Chen,Fu-Quan

doi:10.3892/ijmm.2015.2236

Association between histone deacetylases and the loss of cochlear hair cells: Role of the former in noise-induced hearing loss

Authors:
- Li-Ting Wen
- Jie Wang
- Ye Wang
- Fu-Quan Chen
View Affiliations

Affiliations: Department of Otolaryngology-Head and Neck Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China
Published online on: June 5, 2015 https://doi.org/10.3892/ijmm.2015.2236
Pages: 534-540

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Noise-induced hearing loss (NIHL) is one of the most frequent disabilities in industrialized countries. It has been demonstrated that hair cell loss in the auditory end organ may account for the majority of ear pathological conditions. Previous studies have indicated that histone deacetylases (HDACs) play an important role in neurodegenerative diseases, including hearing impairment, in older persons. Thus, we hypothesized that the inhibition of HDACs would prevent hair cell loss and, consequently, NIHL. In the present study, a CBA/J mouse model of NIHL was established. Following an injection with the HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), the expression levels of HDAC1, HDAC4 and acetyl-histone H3 (Lys9) (H3‑AcK9) were measured. The number of hair cells was quantified and their morphology was observed. The results revealed that 1 h following exposure to 110 dB SPL broadband noise, there was a significant increase in HDAC1 and HDAC4 expression, and a marked decrease in the H3‑AcK9 protein levels, as shown by western blot analysis. Pre-treatment with SAHA significantly inhibited these effects. Two weeks following exposure to noise, the mice exhibited significant hearing impairment and an obvious loss in the number of outer hair cells. An abnormal cell morphology with cilia damage was also observed. Pre-treatment with SAHA markedly attenuated these noise‑induced effects. Taken together, the findings of our study suggest that HDAC expression is associated with outer hair cell function and plays a significant role in NIHL. Our data indicate that SAHA may be a potential therapeutic agent for the prevention of NIHL.

View Figures

View References

1	Sliwinska-Kowalska M and Davis A: Noise-induced hearing loss. Noise Health. 14:274–280. 2012. View Article : Google Scholar : PubMed/NCBI
2	Goodyear RJ, Jones SM, Sharifi L, Forge A and Richardson GP: Hair bundle defects and loss of function in the vestibular end organs of mice lacking the receptor-like inositol lipid phosphatase PTPRQ. J Neurosci. 32:2762–2772. 2012. View Article : Google Scholar : PubMed/NCBI
3	Chen FQ, Schacht J and Sha SH: Aminoglycoside-induced histone deacetylation and hair cell death in the mouse cochlea. J Neurochem. 108:1226–1236. 2009. View Article : Google Scholar : PubMed/NCBI
4	Shakespear MR, Halili MA, Irvine KM, Fairlie DP and Sweet MJ: Histone deacetylases as regulators of inflammation and immunity. Trends Immunol. 32:335–343. 2011. View Article : Google Scholar : PubMed/NCBI
5	Gao L, Cueto MA, Asselbergs F and Atadja P: Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem. 277:25748–25755. 2002. View Article : Google Scholar : PubMed/NCBI
6	Morrison BE, Majdzadeh N, Zhang X, Lyles A, Bassel-Duby R, Olson EN and D’Mello SR: Neuroprotection by histone deacetylase-related protein. Mol Cell Biol. 26:3550–3564. 2006. View Article : Google Scholar : PubMed/NCBI
7	De Ruijter A, Van Gennip A, Caron H, Kemp S and van Kuilenburg A: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 370:737–749. 2003. View Article : Google Scholar
8	Sadri-Vakili G and Cha JH: Mechanisms of disease: histone modifications in Huntington’s disease. Nat Clin Pract Neuro. 2:330–338. 2006. View Article : Google Scholar
9	Strasák L, Bártová E, Harnicarová A, Galiová G, Krejcí J and Kozubek S: H3K9 acetylation and radial chromatin positioning. J Cell Physiol. 220:91–101. 2009. View Article : Google Scholar : PubMed/NCBI
10	Jiang H, Sha SH and Schacht J: Kanamycin alters cytoplasmic and nuclear phosphoinositide signaling in the organ of Corti in vivo. J Neurochem. 99:269–276. 2006. View Article : Google Scholar : PubMed/NCBI
11	Hiebert SW and Stengel KR: Class I HDACs affect DNA replication, repair and chromatin structure: implications for cancer therapy. Antioxid Redox Signal. Jun 26–2014.Epub ahead of print.
12	Feng W, Zhang B, Cai D and Zou X: Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. Cancer Lett. 347:183–190. 2014. View Article : Google Scholar : PubMed/NCBI
13	Rikiishi H: Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol. 2011:Article ID 830260. 2011. View Article : Google Scholar : PubMed/NCBI
14	Rabinowitz PM: Noise-induced hearing loss. Am Fam Physician. 61:2759–2760. 2000.
15	Nair C: Noise-induced hearing loss. InnovAiT. 7:204–208. 2014.
16	Kingston RE and Narlikar GJ: ATP-dependent remodeling and acetylation as regulators of chromatin fluidity. Genes Dev. 13:2339–2352. 1999. View Article : Google Scholar : PubMed/NCBI
17	Stilling RM and Fischer A: The role of histone acetylation in age-associated memory impairment and Alzheimer’s disease. Neurobiol Learn Mem. 96:19–26. 2011. View Article : Google Scholar : PubMed/NCBI
18	Song C, Kanthasamy A, Anantharam V, Sun F and Kanthasamy AG: Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegeneration. Mol Pharmacol. 77:621–632. 2010. View Article : Google Scholar : PubMed/NCBI
19	Gräff J and Tsai LH: Histone acetylation: molecular mnemonics on the chromatin. Nat Rev Neurosci. 14:97–111. 2013. View Article : Google Scholar : PubMed/NCBI
20	Bassett SA and Barnett MP: The role of dietary histone deacetylases (HDACs) inhibitors in health and disease. Nutrients. 6:4273–4301. 2014. View Article : Google Scholar : PubMed/NCBI
21	Zwergel C, Valente S, Jacob C and Mai A: Emerging approaches for histone deacetylase inhibitor drug discovery. Expert Opin Drug Discov. 10:599–613. 2015. View Article : Google Scholar : PubMed/NCBI
22	Konsoula Z and Barile FA: Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders. J Pharmacol Toxicol Methods. 66:215–220. 2012. View Article : Google Scholar : PubMed/NCBI
23	Vieyra D, Loewith R, Scott M, Bonnefin P, Boisvert FM, Cheema P, Pastyryeva S, Meijer M, Johnston RN and Bazett-Jones DP: Human ING1 proteins differentially regulate histone acetylation. J Biol Chem. 277:29832–29839. 2002. View Article : Google Scholar : PubMed/NCBI
24	Marks PA, Miller T and Richon VM: Histone deacetylases. Curr Opin Pharmacol. 3:344–351. 2003. View Article : Google Scholar : PubMed/NCBI
25	Chuang DM, Leng Y, Marinova Z, Kim HJ and Chiu CT: Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 32:591–601. 2009. View Article : Google Scholar : PubMed/NCBI
26	Halili MA, Andrews MR, Sweet MJ and Fairlie DP: Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem. 9:309–319. 2009. View Article : Google Scholar : PubMed/NCBI
27	Huang L: Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J Cell Physiol. 209:611–616. 2006. View Article : Google Scholar : PubMed/NCBI
28	Dietz KC and Casaccia P: HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacol Res. 62:11–17. 2010. View Article : Google Scholar : PubMed/NCBI
29	Jia H, Pallos J, Jacques V, Lau A, Tang B, Cooper A, Syed A, Purcell J, Chen Y, Sharma S, et al: Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington’s disease. Neurobiol Dis. 46:351–361. 2012. View Article : Google Scholar : PubMed/NCBI
30	Soragni E, Xu C, Cooper A, Plasterer HL, Rusche JR and Gottesfeld JM: Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases. Methods Mol Biol. 793:495–508. 2011. View Article : Google Scholar : PubMed/NCBI
31	Roger T, Lugrin J, Le Roy D, Goy G, Mombelli M, Koessler T, Ding XC, Chanson AL, Reymond MK and Miconnet I: Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood. 117:1205–1217. 2011. View Article : Google Scholar
32	Kim HJ and Bae SC: Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 3:166–179. 2011.PubMed/NCBI
33	Piekarz R and Bates S: A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des. 10:2289–2298. 2004. View Article : Google Scholar : PubMed/NCBI
34	Prince HM, Bishton MJ and Harrison SJ: Clinical studies of histone deacetylase inhibitors. Clin Cancer Res. 15:3958–3969. 2009. View Article : Google Scholar : PubMed/NCBI